| INTRODUCTION
The steadily increased use of registry-based data in the last decades has resulted in valuable possibilities to conduct large-sample and high-quality pharmacoepidemiological studies for a diversity of research questions, including drug utilization, efficacy, and safety.
The centralized national prescription registries in the Nordic countries represent valuable potential data resources with their possibilities of long-term population-based record linkage. 1 Self-reported and interview-based validation studies of Danish and Finnish prescription registries have shown them to be valid sources of drug use; however, agreement between interviews and registries notably differs depending on the algorithm used to assess adherence, as well as drug class. [2] [3] [4] Recently, our group showed that agreement between the prescription-registry-modeling method PRE2DUP (a prescription-based design to estimate continuous drug use) and a randomized comparative interview-based study was very good or good, with regard to person-level comparisons for 93% of the participants. 5, 6 Corresponding levels of agreement on drug use based on registries and either self-reports or interviews in previous European studies have at most been moderate or good. [7] [8] [9] [10] Although interview-based studies are frequently used as a reference method for evaluation of drug use, they are encumbered with confirmation and recall bias. 11, 12 Moreover, such methodology may also change the drug-use and reporting behavior of the participants, in general, by increasing both drug purchases and intake through "white-coat adherence" (increase in adherence in the days preceding a health care contact). 13 The latter phenomenon is an important therapeutic intervention per se, but results in artefactual inflation when inferences are made regarding estimated drug use in the general population.
Blood or urine analyses of prescribed, or non-prescribed drugs, represent a direct objective and biological measure of drug use.
14 Furthermore, such analyses may also confirm therapeutic drug concentrations in evaluation of intended efficacy. Nevertheless, anticipated body-fluid sampling is, as in the case with interviews, associated with alterations in drug-use behavior. A few studies have implemented unplanned blood or urine sampling, to investigate unknown co-medication and non-adherence to prescribed medications 11, 15, 16 ; however, all of these studies have been conducted in inpatient-or outpatient-care settings for a limited number of selected substances and are thus prone to selection bias.
Body-fluid sampling within the field of forensic medicine is performed unannounced, in the absence of practical and economic constraints. In general, forensic sampling occurs in the context of a criminal investigation which necessitates the testing of a broad range of substances; however, routines for forensic-toxicological testing still vary worldwide regarding case inclusion and selection of assayed substances, with targeted testing being a highly common forensic practice.
The routines for forensic-toxicological analyses in Sweden are globally unique: regardless of suspected cause of death or without any expressed request from the medical examiner, the broad range of legal and illegal substances is routinely tested for in each case. • Forensic-toxicological detection of pharmacological substances post mortem is the closest possible proxy for ongoing pharmacotherapy and its conceivable biological effects.
• The main limitation in our study is the absence of detailed data on the time interval between last dosage and death, which for substances with short half-lives has precluded confirmation of pharmacological nonadherence. had been admitted to a hospital in the 3 days preceding death, or had spent more than 30 days cumulatively on a hospital ward during the 183 days preceding death were also excluded (n = 3311). From the study sample (n = 18 627), separate analyses were also performed on subsets of subjects: subjects whose main cause of death was related to cardiovascular morbidity (ICD-10 codes I00-I99, 24 n = 7843) and subjects whose main cause of death was related to non-cardiovascular morbidity (ICD-10 codes A00-H99; J00-Y98, 24 n = 10 784), including a smaller subset who had died in a vehicle accident (ICD-9 codes E800-E848; and ICD-10 codes V01-V99, 23, 24 n = 1544).
| Toxicological analyses
Postmortem toxicological analysis at NFBM's Department of Forensic Genetics and Forensic Toxicology was performed in 2 stages, using an in-house database of more 500 substances (including nearly 200
substances routinely assayed in all instances of forensically investigated deaths). After initial screening using liquid-chromatography time-of-flight technology, concentrations of substances detected upon screening were determined by gas chromatography-mass spectrometry or liquid chromatography-tandem mass spectrometry. 25, 26 Analytical methods were accredited with validated detection thresholds for each analyzed substance. 
| Exposure
For the present study, all routinely screened prescription drugs were included, with the exception of addictive substances (benzodiazepines, opioids, and narcotic stimulants) that are readily sought after and acquired illegally. The included substances were required to be detectable by the accredited analytical methods at concentrations on par with, or below, the lower limit of each substance's recognized therapeutic range (Table S1 ). 28 Registry and NBFM's Toxbase, a history of dispensed prescriptions of at least 183 days before death was available for all subjects.
| PRE2DUP
The data from the Swedish National Prescription Registry were modeled using the PRE2DUP method. 6 This method is based on sliding FIGURE 1 Flow chart of exclusions for the study sample averages of daily dose (in defined daily doses) calculated for each drug substance over time. The method takes into account personal drug purchasing behavior and stockpiling of drugs. For single purchases, the method uses typical durations of the purchased package in the study sample. As the focus in this particular study was drug use at the time of death, registry-based data always represent an individual's last purchase; thus, the duration of the last purchase is the principal evaluated factor. The dates of death were not known to the PRE2DUP modelers (H.T., A.T.).
| Statistical analyses
The assessment of the agreement between PRE2DUP-modeled drug use and toxicological findings was made at the personal level for all 
| RESULTS
Out of 18 627 subjects included in the study, 62.9% were under the age of 65 with an overall mean age of 58.4 years. Women represented 23.7% of the sample. The most common main cause of death, at 41.1%, was illness related to the circulatory system (ICD10: I00-I99 24 ), whereas the second most common main cause of death, at 33.0%, was a group of external causes of morbidity, including transport accidents, accidental exposure to electric current, or exposure to forces of nature (ICD10: V01-Y98 24 ), yet excluding certain or uncertain suicide (ICD10: Y10-Y34; X60-X84 24 ). The number of autopsies performed yearly was relatively constant throughout the study period. A positive toxicological screening for ethanol was found in 35.3% of the subjects. Alcohol-related disorders taken as a group, were, at 22.1%, after ischemic heart disease (35.5%), the second most common comorbid condition adjudged to have contributed to the cause of death; however, they constituted the most common condition based on registered previous inpatient care (Table 1) .
Overall Plotting the detection rate versus biological half-life of each substance (Table S1) prescriptions without matching positive toxicology), analyses were performed among users of the commonly prescribed cardiovascular drug metoprolol and the antipsychotic drug quetiapine, because both drugs had displayed less than "good" Cohen's kappa agreement between toxicology and registry data. In the event, comparisons of the subgroups revealed the following differences (Table 3) .
True-positive users of metoprolol had a higher mean age, higher number of subjects older than 65 years of age, and higher proportion of females than false-positive users (with all differences being statistically significant), whereas no statistical significant differences were seen between true-positive and false-positive users of quetiapine. With regard to post-mortem positivity for alcohol or a registered date of death during a Swedish holiday, there were no statistically significant differences between subgroups for either metoprolol or quetiapine; likewise, there was no significant difference with regard to registered main cause of death for either drug.
True-positive users of metoprolol had a statistically significant higher frequency of comorbid cardiovascular conditions compared to false-positive users, whereas no statistical significant differences were found in this regard among quetiapine users. However, both falsepositive metoprolol and false-positive quetiapine users had statistically significant higher frequencies of both lower strength formulation and lower prescribed dosages recorded in their last dispensed prescription than their within-group counterparts. A shorter time since last purchase (less than 31 days) was significantly more common among true-positive quetiapine users than false-positive users of the drug. A post-hoc analysis stratifying for ethanol status at autopsy revealed no marked differences with regard to predicted adherence to cardiovascular drugs (Table S6) .
| DISCUSSION
This nationwide postmortem study included information on nearly all forensically investigated incidents of suspected unnatural death in 
| Agreement
The agreement between PRE2DUP-modeled drug use and toxicologi- For the complete list of included ICD10 diagnoses, see Table S5 .
COPD, chronic obstructive pulmonary disease.
were prescribed at low dosages; or drugs whose concentrations, despite adherence, had sunk to low levels at the time of death.
This suspicion was, in part, confirmed among false-positive metoprolol users, who, when compared with their true-positive counterparts, turned out more often to have been prescribed both lower-strength tablets and lower dosage of these tablets at last drug purchase.
Another possible explanation for the measured predicted low adherence is that some drugs are prescribed at sub-therapeutic dosage as part of an individualized treatment regimen, or prescribed to be taken as needed in off-label use, as when propranolol and other beta-blockers are prescribed for anxiety and other psychiatric conditions. 35 Moreover, as PRE2DUP calculates time of drug use with the help of information regarding estimated dosing and dispensed 
| Comparison with previous studies
In a previous study, we demonstrated that PRE2DUP outperforms 
| Strengths and limitations
The present dataset is unique in that it comprises robust forensic- The PRE2DUP method has demonstrated high accuracy and good validity when assessed in comparison to interviews. 5 Thus, the exposure estimates produced by the PRE2DUP method is presumed to be reliable, especially for regularly used drugs. For drug use on "as-needed" basis, the method is not able to detect or predict the exact days when a drug was taken; instead, it produces drug-use periods starting from the purchase date and lasting as long as the drug would have been used on a regular basis, a procedure that may result in false predictions of discontinued use. As demonstrated in the present study, however, the phenomenon of d Metoprolol ≤50 mg, quetiapine ≤100-mg tablet strength.
e Among those with exact dose provided in the prescription (N = 1606 for metoprolol, N = 90 for quetiapine), ≤100 mg for metoprolol and ≤200 mg for quetiapine (according to median doses used in the sample). COPD, chronic obstructive pulmonary disease.
a positive correlation between drug half-life and probability of detection upon toxicology does not appear to obtain for beta-blockers.
Low rates of predicted adherence to beta-blockers and other cardiovascular drugs in the present study are believed to be related to a number of factors, including off-label use and other unconventional dosing, as well as true non-adherence (which, in turn, is presumed to be conditioned by still other factors, such as a medication's intended and unintended pharmacodynamic effects, as well as a subject's disease insight and treatment motivation). Finally, the results of the study suggest that, at any given time point, on average only every other instance of dispensed drug use will be associated with therapeutic blood levels of the medication in question.
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